AMC enters the week with a striking insider signal: CEO Adam Aron purchased 250,000 shares on May 19 at $1.38, committing $344,350 of his own money at a stock trading near its one-month low.
The buy lands against a backdrop that has grown more complicated for bears. Short interest at nearly 15% of the free float remains high in absolute terms, but it has pulled back sharply from a recent spike. At its peak around May 5, estimated shorts climbed to roughly 16.6% of float — and in early April the figure briefly touched above 18%. The retreat since then has been meaningful, with short shares down about 12% over the past month and almost 2% on the week. What makes this week's lending data particularly notable is the collapse in borrowing pressure: cost to borrow has tumbled to 0.81% from above 1.9% in early May, a drop of more than 35% in a single week. Borrow availability has also swung dramatically. On May 5, availability briefly fell to essentially zero — every share in the lending pool lent out, the tightest the market had been in at least a year. By May 19 it had rebounded to 440%, a near-complete reversal that signals the short squeeze conditions of early May have fully unwound.
Options traders are leaning clearly bullish. The put/call ratio is at its lowest reading of the year at 0.16, more than 1.3 standard deviations below its 20-day average of 0.19 and well beneath the 52-week high of 0.31. That's an unusually call-heavy posture for a stock with this much short interest — traders appear to be positioning for upside, not protection. The combination of a retreating short base, collapsing borrow costs, and a lopsided call skew gives the near-term setup a more constructive feel than the underlying operational story would normally support.
Analyst opinion is divided but tilting negative. The most recent post-earnings actions tell contrasting stories: Benchmark upgraded AMC to Buy with a $2.50 target on May 6, while Citigroup maintained Sell and nudged its target to just $1.20 on May 7. The consensus mean target sits at $1.95 — a 43% premium to the $1.36 close — though that figure leans heavily on the single bull outlier. The bear case is straightforward: attendance is structurally under pressure, fixed costs remain punishing, and the company's own guidance implies an adjusted EBITDA loss this year despite projecting 53% EBITDA growth in 2026. Net leverage at 9.3x is elevated even as it trends lower. The bull case rests on a strong 2026 film slate driving margin expansion to 12% and EBITDA recovering meaningfully by 2027. Factor scores add nuance: the forward EPS growth rank is at the 87th percentile — genuine improvement expected — but the EV/EBIT rank is in the bottom 6% of the universe, reflecting how expensive the enterprise value looks relative to earnings power today.
Peer exhibitors had a mixed week. MCS (Marcus Corporation) edged up 3.2% on the week, broadly in line with AMC's 1.5% gain. CURI fell 11.8%, while DIS dropped 3.6%. AMC's modest outperformance of the peer group is consistent with the recent pattern of short-base reduction and call-heavy options flow providing episodic support — without any fundamental catalyst changing the structural picture for theatrical exhibition.
Aron's open-market purchase is the detail worth tracking closely from here. The next earnings event is scheduled for August 4, and the pattern from recent prints suggests volatility: the May earnings release saw a 13% jump on day one, followed by a 7.6% decline over the subsequent five sessions. Whether the CEO's buy reflects confidence in the upcoming quarter or a broader strategic statement about valuation at current levels is the question the market will be digesting heading into summer.
See the live data behind this article on ORTEX.
Open AMC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
